The role of lymphotoxin in autoimmune disease (ASI 2012) - Nov 20, 2012 - P1, N=65; NCT00888745; "In a randomized, double-blind, placebo-controlled phase I study of 65 patients with active RA, we show the safety and activity of pateclizumab. These data indicate that depleting Th1 and Th17 with anti LT mAb may be beneficial in the treatment of autoimmune disease."
P1 data • Rheumatoid Arthritis
|
|
42nd Annual Scientific Meeting of the Australasian Society for Immunology, 2-6 Dec 12
|
|
Abstract | 8
...We generated a humanized anti-LTa mAb (pateclizumab) that interferes with binding of LT trimers to its cognate receptors, and provide supporting biochemical and structural studies. In a randomized, double-blind, placebo-controlled phase I study of 65 patients with active RA, we show the safety and activity of pateclizumab. These data indicate that depleting Th1 and Th17 with anti LT mAb may be beneficial in the treatment of autoimmune disease.
|